Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Teva gains FDA nod for Xgeva biosimilar

2 October 2026 · By · Wire by Fusion42

Published

2 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at drugstorenews.com →

◆ Verified

Fusion42 · 2 October 2026 · Fusion42 review

The FDA has approved Teva's Degevma as a biosimilar to Amgen's Xgeva, broadening access to biologic treatments for oncology-related bone disease and expanding Teva's denosumab biosimilar portfolio.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your oncology biosimilar now faces a new competitor with FDA approval of Teva’s biosimilar to Xgeva, making pricing and market access more challenging in US biologics. Consider accelerating your go-to-market plans or exploring differentiation beyond pricing.

◆ Coverage

1 source · 2 Oct 2026

◆ Related on Wire

◆ Topics

BiotechbiosimilarFDA-approvaloncologydenosumabTeva